ErbB-2 induces the cyclin D1 gene in prostate epithelial cells in vitro and in vivo

Cancer Research

Volumn 67, Issue 9, 2007, Pages 4364-4372

  Casimiro, Mathew ^a   Rodriguez, Olga ^b   Pootrakul, Llana ^c   Aventian, Maral ^b   Lushina, Nadia ^b   Cromelin, Caroline ^b   Ferzli, Georgina ^b   Johnson, Kevin ^b   Fricke, Stanley ^b   Diba, Fantahun ^b   Kallakury, Bhaskar ^b   Ohanyerenwa, Chioma ^b   Chen, Maxine ^d   Ostrowski, Michael ^e   Hung, Mien Chie ^f   Rabbani, Shafaat A ^g   Datar, Ram ^c   Cote, Richard ^c   Pestell, Richard ^a   Albanese, Chris ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d RUTGERS UNIVERSITY   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; CARCINOGENESIS; CELL CYCLE; CELL STRAIN LNCAP; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; REGULATOR GENE;

ANIMALS; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYCLIN D1; EPITHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-1; HUMANS; MALE; MICE; PROMOTER REGIONS (GENETICS); PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RECEPTOR, ERBB-2; RNA, SMALL INTERFERING;

EID: 34249301737     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1898     Document Type: Article

References (48)

1. Sanchez KM, Sweeney CJ, Mass R, et al. Evaluation of HER-2/neu expression in prostatic adenocarcinoma; a requested for a standardized, organ specific methodology. Cancer 2002;95:1650-5.
2. Fossa A, Lilleby W, Fossa SD, Gaudernack G, Torlakovic G, Berner A. Independent prognostic significance of HER-2 oncoprotein expression in pN0 prostate cancer undergoing curative radiotherapy. Int J Cancer 2002;99:100-5.
3. Morris MJ, Reuter VE, Kelly WK, et al. HER-2 profiling and targeting in prostate carcinoma. Cancer 2002;94:980-6.
4. Myers RB, Srivasatava S, Oelschlager DK, Grizzle WE. Expression of p130erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J Natl Cancer Inst 1994;86:1140-5.
5. Signoretti S, Montironi R, Manola J, et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 2000;92:1918-25.
6. Shi Y, Chatterjee SJ, Brands FH, et al. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations. BJU Int 2006;97:170-8.
7. Osman I, Mikhail M, Shuch B, et al. Serum levels of shed Her2/neu protein in men with prostate cancer correlate with disease progression. J Urol 2005;174:2174-7.
8. Lyne JC, Melhem MF, Finley GG, et al. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biological effects on prosatte cancer cells in vitro. Cancer J Sci Am 1997;3:21-30.
9. Grasso AW, Wen D, Miller CM, Rhim JS, Pretlow TG, Kung HJ. ErbB kinases and NDF signaling in human prostate cancer cells. Oncogene 1997;15:2705-16.
10. Wen Y, Hu MC, Makino K, et al. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 2000;60:6841-5.
11. Pfeil K, Eder IE, Putz T, et al. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells. Prostate 2004;58:259-68.
12. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci U S A 1999;96:5458-63.
13. Pianetti S, Arsura M, Romieu-Mourez R, Coffey RJ, Sonenshein GE. Her-2/neu overexpression induces NF-κB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IκB-α that can be inhibited by the tumor suppressor PTEN. Oncogene 2001;20:1287-99.
14. Lessard L, Mes-Masson AM, Lamarre L, Wall L, Lattouf JB, Saad F. NF-κB nuclear localization and its prognostic significance in prostate cancer. BJU Int 2003;91:417-20.
15. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 2004;6:517-27.
16. Kwong KY, Hung MC. A novel splice variant of HER2 with increased transformation activity. Mol Carcinog 1998;23:62-8.
17. Pestell RG, Albanese C, Reutens AT, Segall JE, Lee RJ, Arnold A. The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocr Rev 1999;20:501-34.
18. Lee RJ, Albanese C, Fu M, et al. Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol Cell Biol 2000;20:672-83.
19. Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001;411:1017-21.
20. Hulit J, Wang C, Li Z, et al. Cyclin D1 genetic heterozygosity regulates colonic epithelial cell differentiation and tumor number in ApcMin mice. Mol Cell Biol 2004;24:7598-611.
21. Perry JE, Grossmann ME, Tindall DJ. Epidermal growth factor induces cyclin D1 in a human prostate cancer cell line. Prostate 1998;35:117-24.
22. Han E, Lim JT, Arber N, Rubin MA, Xing WQ, Weinstein IB. Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors. Prostate 1998;35:95-101.
23. Drobnjak M, Osman I, Scher HI, Fazzari M, Cordon-Cardo C. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res 2000;6:1891-5.
24. Chen Y, Martinez LA, LaCava M, Coghlan L, Conti CJ. Increased cell growth and tumorigenicity in human prostate LNCaP cells by overexpression to cyclin D1. Oncogene 1998;16:1913-20.
25. Huynh H, Nguyen TT, Chan E, Tran E. Inhibition of ErbB-2 and ErbB-3 expression by quercetin prevents transforming growth factor α (TGF-α)- and epidermal growth factor (EGF)-induced human PC-3 prostate cancer cell proliferation. Int J Oncol 2003;23:821-9.
26. Ma Z, Hung Nguyen T, Hoa Huynh T, Tien Do P, Huynh H. Reduction of rat prostate weight by combined quercetin-linasteride treatment is associated with cell cycle deregulation. J Endocrinol 2004;181:493-507.
27. Rodriguez O, Fricke S, Chien C, et al. Contrast-enhanced in vivo imaging of breast and prostate cancer cells by MR1. Cell Cycle 2006;5:113-9.
28. Albanese C, Johnson J, Watanabe G, et al. Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem 1995;270:23589-97.
29. Albanese C, D'Amico M, Reutens AT, et al. Activation of the cyclin D1 gene by the E1A-associated protein p300 through AP-1 inhibits cellular apoptosis. J Biol Chem 1999;274:34186-95.
30. Albanese C, Wu K, D'Amico M, et al. IKKα regulates mitogenic signaling through transcriptional induction of cyclin D1 via Tcf. Mol Biol Cell 2003;14:585-99.
31. v-src induction of cyclin D1 requires collaborative interactions between the extracellular signal-regulated kinase, p38, and Jun kinase pathways: a role for cAMP response element-binding protein and activating transcription factor-2 in pp60v-src signaling in breast cancer cells. J Biol Chem 1999;274:7341-50.
32. Pestell RG, Albanese C, Watanabe G, et al. Stimulation of the P-450 side chain cleavage (CYP11A1) promoter through ras- and Ets-2-signaling pathways. Mol Endocrinol 1996;10:1084-94.
33. Mazumdar A, Adam L, Boyd D, Kumar R. Heregulin regulation of urokinase plasminogen activator and its receptor: human breast epithelial cell invasion. Cancer Res 2001;61:400-5.
34. Wang H, Yang L, Jamaluddin MS, Boyd DD. The Kruppel-like KLF4 transcription factor, a novel regulator of urokinase receptor expression, drives synthesis of this binding site in colonic crypt luminal surface epithelial cells. J Biol Chem 2004;279:22674-83.
35. Fricke S, Rodriguez O, Vanmeter J, et al. In vivo magnetic resonance volumetric and spectroscopic analysis of mouse prostate cancer models. Prostate 2006;66:708-17.
36. Shi SR, Cote RJ, Taylor CR. Antigen retrieval immunohistochemistry: past, present, and future. J Histochem Cytochem 1997;45:327-43.
37. Shi Y, Brands FH, Chatterjee S, et al. Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. J Urol 2001;166:1514-9.
38. Xiao D, Chinnappan D, Pestell R, Albanese C, Weber HC. Bombesin regulates cyclin D1 expression through the early growth response protein Egr-1 in prostate cancer cells. Cancer Res 2005;65:9934-42.
39. Yang HY, Zhou BP, Hung MC, Lee MH. Oncogenic signals of HER-2/neu in regulating the stability of the cyclin-dependent kinase inhibitor p27. J Biol Chem 2000;275:24735-9.
40. 1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. J Biol Chem 2003;278:46862-8.
41. Park JH, Walls JE, Galvez JJ, et al. Prostatic intra-epithelial neoplasia in genetically engineered mice. Am J Pathol 2002;161:727-35.
42. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999;5:280-5.
43. Gregory CW, Whang YE, McCall W, et al. Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin Cancer Res 2005;11:1704-12.
44. Reutens AT, Fu M, Wang C, et al. Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner. Mol Endocrinol 2001;15:797-811.
45. Lim JT, Mansukhani M, Weinstein IB. Cyclin-dependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells. Proc Natl Acad Sci U S A 2005;102:5156-61.
46. Li Z, Szabolcs M, Terwilliger JD, Efstratiadis A. Prostatic intraepithelial neoplasia and adenocarcinoma in mice expressing a probasin-Neu oncogenic transgene. Carcinogenesis 2006;27:1054-67.
47. Albanese C, Rodriguez O, Johnson MD, Fricke S. Models of prostate cancer. Drug Discov Today Disease Models 2005;2:7-13.
48. Jones RB, Gordus A, Krall JA, Macbeath G. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 2005;439: 169-74.